



## Neurotech completes shipment of 100 Mente Autism devices to various countries

### KEY HIGHLIGHTS

- 100 devices shipped to Australia, Europe and Middle East since launch in August
- New distribution partners engaged in Holland & Yemen
- 20 research devices shipped to Italy and Middle East in advance of commencing multi-site studies

**Perth, Australia & Malta – 4 October 2018** – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce that it has shipped 100 devices since the release of the improved Autism device in August.

Of these 100 devices, 50 devices were shipped to the Company’s Italian distributor, Promosalute. Further orders from Italy are expected by the end of the year.

Promosalute will be ramping up its marketing campaigns in the coming weeks, promoting and distributing the devices through its network, neurofeedback centres and other channels.

The other 50 devices were shipped to Australia, Europe (including Netherlands, Greece, Germany, United Kingdom) and the Middle East. In addition, 20 **research** devices were shipped to Italy and the Middle East, in anticipation of commencing multi-site studies in these regions. These studies are aimed at further validating the product in different markets, generating awareness and acceptance of the technology in the regions, in addition to supporting potential reimbursement schemes.

### NEW DISTRIBUTION PARTNERS APPOINTED

Neurotech has also appointed two new distribution partners in Holland and Yemen. Following the signing of the agreements, an initial batch of devices were also shipped to these countries, as included above.

The Dutch partner, Neurobics Ltd, has commenced marketing and information campaigns and will be using new marketing assets to promote Mente Autism in the local media and with key opinion leaders.

Wolfgang Storf, Neurotech’s CEO, said: “This is another important step in our commercial strategy as we look to expand our order book and also engage with new distribution partners in new markets. I am confident that we are in an excellent position to create value for our shareholders and tap into new opportunities to grow our business.”

---

### Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

## CLINICAL TRIAL RESULTS TO BE PRESENTED AT UK CONFERENCE

Dr Ahmed Hankir, Professor of Psychiatry, Carrick Institute, and Senior Research Fellow at BCMHR in association with University of Cambridge, UK will be presenting the outcomes of the study, *“The Treatment of Autism Spectrum Disorder With Auditory Neurofeedback: A Randomized Placebo Controlled Trial Using the Mente Autism Device”* at the Royal College of Psychiatrists (UK) Faculty of Psychiatry conference on Intellectual Disability, on 4<sup>th</sup> and 5<sup>th</sup> October 2018 in Liverpool, United Kingdom.

Dr Hankir is a co-author on the Mente study published in *Frontiers in Neurology*, which has been viewed almost 24,000 times since its publication in July, setting a record for having more reads than 99% of the studies published in *Frontiers* journals.

Dr Hankir will deliver an oral presentation of the study as well as a poster presentation.

Investigators found statistically significant positive changes in children with Autism Spectrum Disorder after a 12-week trial using the Mente Autism device.

-ends-

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420